A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-06-15
Adverse events
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-24 (study day 455); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-04 (study day 496); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-11-22 (study day 514); relationship: not assessed
Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-27 (study day 611); relationship: not assessed; serious criteria: hospitalization
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-05-24 (study day 698); relationship: N
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-11-07 (study day 865); relationship: not assessed
Data queries
No data queries.